You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020167026
Dec 20204009
Jan 20214508
Feb 202159010
Mar 202182013
Apr 202176013
May 20211608
Jun 2021008
Jul 20210016
Aug 2021007
Sep 20210030
Oct 202132071
Nov 202142021
Dec 202120011
Jan 202224020
Feb 202214011
Mar 202226014
Apr 20225208
May 202244015
Jun 202242013
Jul 20226805
Aug 202290012
Sep 202264014
Oct 20226005
Nov 202262012
Dec 202256013
Jan 202388021
Feb 2023126015
Mar 20239405
Apr 20237807
May 20237008
Jun 20236009
Jul 202392013
Aug 2023124014
Sep 2023154010
Oct 20238408
Nov 202396011
Dec 2023106014
Jan 20243807
Feb 20249006
Mar 2024112021
Apr 2024114032
May 2024128016
Jun 20248405
Jul 2024146015
Aug 2024124020
Sep 2024122012
Oct 2024132019
Nov 2024116018
Dec 202478010
Jan 202562039
Feb 202532018
Mar 20250013
Apr 20250014
May 2025007
Jun 20250015
Total37310815